Predictors of endoscopic prophylaxis for rebleeding in esophageal varices combined type 2 gastroesophageal varices [post]

2019 unpublished
and Aim Decompensated cirrhosis patients with esophageal varices (EVs) combined type 2 gastroesophageal varices (GOV2) have rebleeding risk after endoscopic prophylaxis. This study was performed to evaluate the preventive efficacy of endoscopic treatment in patients with EVs combined GOV2, and seek out the risk factor of rebleeding. Methods We performed a single-center, observational, retrospective study of patients with EVs combined GOV2 extracted from hospitalization. The biochemical
more » ... iochemical examination, demographics, endoscopic performance and treatment methods of patients undergoing endoscopic treatment were collected. All patients were observed until 1-year, or loss to follow-up. The predictors parameter of rebleeding were analyzed by logistic regression analysis Results A total of 124 patients underwent endoscopic treatment, including 2 (1.6%) patients failed to stop bleeding, 19 (15.3%) patients loss to follow-up. 103 patients were observed until 1-year, including 11 (10.7%) patients had rebleeding. The results had indicated EVs+GOV2 with GOV1, Age, PTA, Bilirubin, Platelet count, Child-Pugh, MELD were associated with rebleeding at 1-year in patients with EVs combined GOV2. Multivariate logistic analysis defined that Age, EVs+GOV2 with GOV1, Bilirubin, PTA were independent risk factor for rebleeding.
doi:10.21203/rs.2.18037/v1 fatcat:s3wj353fqvckfbznsvtoymuitm